PROTAC RET Degrader 1
PROTAC RET Degrader 1 is an orally active, blood-brain barrier-penetrant RET PROTAC degrader with a DC50 of 1.7 nM. PROTAC RET Degrader 1 binds to CRBN and forms a ternary complex with RET, mediating proteasomal degradation of RET, while also selectively mediating the degradation of SALL4. PROTAC RET Degrader 1 inhibits the RET signaling pathway, hERG channel activity, and Cyp3A4 enzyme activity; it suppresses cancer cell growth and induces tumor regression. PROTAC RET Degrader 1 can be used in research related to RET-driven cancers.
(Pink: RET ligand (HY-179308); Blue: Cereblon ligand (HY-179307); Black: linker).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2760847-82-1
- 화학식: C48H57FN12O3
- 분자량:869.04
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
CYP3A4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | DC50 |
1.7 nM
|
Degradation of wild-type RET kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged wild-type RET kinase domain measured by HiBiT tag readout.
Degradation of wild-type RET kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged wild-type RET kinase domain measured by HiBiT tag readout.
|
40823490 |
| HEK-293T | DC50 |
21 nM
|
Degradation of drug-resistant RET G810R kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810R kinase domain measured by HiBiT tag readout.
Degradation of drug-resistant RET G810R kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810R kinase domain measured by HiBiT tag readout.
|
40823490 |
| HEK-293T | DC50 |
3 nM
|
Degradation of drug-resistant RET G810S kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810S kinase domain measured by HiBiT tag readout.
Degradation of drug-resistant RET G810S kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810S kinase domain measured by HiBiT tag readout.
|
40823490 |
| HEK-293T | DC50 |
12 nM
|
Degradation of drug-resistant RET G810C kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810C kinase domain measured by HiBiT tag readout.
Degradation of drug-resistant RET G810C kinase domain in HEK293T cells expressing C-terminal HiBiT-tagged RET G810C kinase domain measured by HiBiT tag readout.
|
40823490 |
In Vitro
PROTAC RET Degrader 1 (compound 20) potently degrades the wild-type RET kinase domain in HEK293T cells, with a DC50 of 1.7 nM and a maximum remaining protein level of 8%; it degrades the drug-resistant RETG810R kinase domain, with a DC50 of 21 nM and a maximum remaining protein rate of 22%; it also degrades the drug-resistant RETG810S and RETG810C kinase domains, with DC50 values of 3 nM and 12 nM, and maximum remaining protein levels of 25% and 31%, respectively[1].
PROTAC RET Degrader 1 binds to CRBN in HEK293T cells, with an IC50 of 10 nM as determined by NanoBRET assay[1].
PROTAC RET Degrader 1 selectively degrades the novel CRBN substrate SALL4 (DC50 = 6.1 μM) in HiBiT-tagged cell lines, without degrading GSPT1 or IKZF1[1].
PROTAC RET Degrader 1 potently inhibits the proliferation of Ba/F3 cells expressing KIF5B-RET fusion proteins carrying drug-resistant mutations (RETG810R, RETV804L, RETY806N, RETL730I)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | CL | T1/2 | Vdss | AUClast | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | i.v. | 18.4 mL/min/kg | 5.3 h | 7.8 L/kg | 814 ng·h/mL | / | / |
| Rat[1] | 1 mg/kg | i.v. | 25.5 mL/min/kg | 8.7 h | 18.2 L/kg | 572 ng·h/mL | / | / |
| Mice[1] | 10 mg/kg | p.o. | / | / | / | 3192 ng·h/mL | 312 ng/mL | 39 % |
| Rat[1] | 10 mg/kg | p.o. | / | / | / | 475 ng·h/mL | 35.4 ng/mL | 8 % |
In Vivo
PROTAC RET Degrader 1 (30 mg/kg; p.o.; single administration) can cross the blood-brain barrier, accumulate in intracranial colorectal cancer PDX tumors driven by the CCDC6-RET fusion, and induce rapid and potent RET degradation as well as pathway inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice received subcutaneous implantation of tumor fragments of RET‑driven NSCLC bearing the KIF5B‑RET fusion (CTG‑0838)[1]
-
Dosage:5 mg/kg (i.v.); 30 mg/kg (p.o.)
-
Administration:i.v.; QD
p.o.; QD -
Result:Achieved tumor regression comparable to Selpercatinib.
Reduced KIF5B-RET protein levels by >50% within 5 hours after single administration.
Retained robust reduction in pSHC at 24 hours after single administration.
Produced sustained degradation of KIF5B-RET with repeated dosing.
-
Animal Model:BALB/c mice received subcutaneous implantation of tumor fragments of colorectal cancer bearing the CCDC6‑RET fusion (CR2518)[1]
-
Dosage:5 mg/kg (i.v.); 30 mg/kg (p.o.)
-
Administration:i.v.; QD
p.o.; QD -
Result:Achieved tumor regression comparable to Selpercatinib.
Chemical Information
-
CAS No. 2760847-82-1
-
분자량 869.04
-
화학식 C48H57FN12O3
-
SMILES
CCC1(CCN(CC1)C2=NC=C(C=C2)C3=NC(C4=CN(N=C4)[C@H]5CC[C@@H](CC5)N6CCC(CC6)C7=C(C=C(C=C7)NC8CCC(NC8=O)=O)F)=CN9N=CC(C#N)=C39)C(NC(C)C)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)